Medincell says Teva wins FDA approval for WELTRUZA olanzapine monthly injection
Bitget2026/10/09 11:56FDA cleared Teva’s WELTRUZA (olanzapine) once-monthly subcutaneous long-acting injectable for adults with schizophrenia, using Medincell technology. Product launch in the U.S. expected in coming weeks; Medincell to receive mid- to high-single-digit royalties on worldwide net sales. Approval triggers a $4 million milestone payment; additional commercial milestones total up to $105 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261009150047) on October 09, 2026, and is solely responsible for the information contained therein.
- FDA cleared Teva’s WELTRUZA (olanzapine) once-monthly subcutaneous long-acting injectable for adults with schizophrenia, using Medincell technology.
- Product launch in the U.S. expected in coming weeks; Medincell to receive mid- to high-single-digit royalties on worldwide net sales.
- Approval triggers a $4 million milestone payment; additional commercial milestones total up to $105 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Concentra shares rise; Jefferies initiates with “Buy” rating
BUZZ-Strategy shares fall after MSCI warns it may be removed from global indices
Chart: As Treasury yields fall, US equity funds attract inflows again
Crypto prices
More
